Journal
IMMUNOLOGICAL INVESTIGATIONS
Volume 41, Issue 6-7, Pages 658-679Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/08820139.2012.689591
Keywords
MWSC; Gliomas; IL4R alpha; Arginase; TAM; Malignancy; Immunosuppression; CD11b; Gr1
Categories
Funding
- National Institutes of Health [2R01NS055140, 2P01 NS40923, 1P01CA132714, P3CA047904]
- Musella Foundation
Ask authors/readers for more resources
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of cells that inhibit anti-tumor immunity through a variety of mechanisms. Malignant gliomas are heavily infiltrated by myeloid cells, some of which appear to share biological functions of MDSCs. Our data with mouse de novo gliomas indicate critical roles of these cells in glioma development. This review summarizes the current understanding of MDSC biology in gliomas and discusses therapeutic interventions that can safely reverse the suppressive effects of MDSCs. The insight gained from these findings may lead to the development of novel immunotherapeutic strategies for gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available